Suton P, et al. - A total of 1,665 patients were analyzed to describe the effectiveness of cisplatin (CDDP) vs cetuximab (C225) given concurrently with radiotherapy as a definitive treatment of p16-positive oropharyngeal cancer (OPC). They recorded a pooled OR for CDDP-based chemoradiotherapy vs C225-based bioradiotherapy of 0.45. They had data from eight studies for the analysis of 2-year locoregional recurrence (LRR). They also reported 0.35 of pooled OR for CDDP-based chemoradiotherapy vs C225-based bioradiotherapy. They found 2.2- and 2.9-fold lower risk of death from any cause and LRR, respectively, in those receiving CDDP with irradiation. Inferior overall survival and higher LRR rates were reported with radiotherapy plus C225 in patients with HPV-positive OPC vs radiotherapy plus CDDP.